A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
Public ClinicalTrials.gov record NCT04597918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.
Study identification
- NCT ID
- NCT04597918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2020
- Primary completion
- Dec 21, 2022
- Completion
- Dec 21, 2022
- Last update posted
- Jun 14, 2026
2020 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bascom Palmer Eye Institute | Naples | Florida | 34103 | — |
| Northwestern Medical Group/Northwestern University | Chicago | Illinois | 60611 | — |
| University Retina and Macula Associates, PC | Oak Forest | Illinois | 60452 | — |
| Raj K. Maturi, MD PC | Indianapolis | Indiana | 46290 | — |
| Cumberland Valley Retina PC | Hagerstown | Maryland | 21740 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Long Is. Vitreoretinal Consult | Great Neck | New York | 11021 | — |
| Charles Retina Institute | Germantown | Tennessee | 38138 | — |
| Retina Res Institute of Texas | Abilene | Texas | 79606 | — |
| Austin Research Center for Retina | Austin | Texas | 78705 | — |
| Retina Consultants of Texas | Houston | Texas | 77030 | — |
| Strategic Clinical Research Group, LLC | Willow Park | Texas | 76087 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04597918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04597918 live on ClinicalTrials.gov.